Baseline Galectin-3 in Patients with Breast Cancer Scheduled for Anthracycline Therapy: Associations with Cardiac Biomarkers, Left Ventricular Function, and HFA-ICOS Risk Stratification
7 affiliations
- 1Non-Commercial Clinical Research Outpatient Clinic, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland
- 2Department of Cancer & Cardio-Oncology Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland
- 3Unit for Screening Studies in Inherited Cardiovascular Diseases, The Cardinal Stefan Wyszynski National Institute of Cardiology, 04-628 Warsaw, Poland
- 4Digital Medicine Center, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland
- 5Cancer Biomarker and Cytokines Laboratory Unit, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland
- 6Department of Brest Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland
- 7Division of Cardiology, Istituto Nazionale Tumori-(Istituto di Ricovero e Cura a Carattere Scientifico) IRCCS-Fondazione G. Pascale, 80131 Naples, Italy
Abstract
The clinical role of galectin-3 (Gal-3) as a biomarker in cardio-oncology remains uncertain. This study evaluated baseline Gal-3 concentrations and their associations with established cardiac biomarkers, left ventricular systolic function, and HFA-ICOS cardiovascular risk categories in patients with breast cancer before anthracycline-based chemotherapy. This cross-sectional baseline analysis included 103 patients enrolled in the EMPACT trial. Gal-3 concentrations were evaluated in relation to high-sensitivity cardiac troponin T (hs-cTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), HFA-ICOS risk categories, and clinical characteristics. Associations were assessed using Pearson correlation analyses and median regression. Mean baseline Gal-3 concentration was 6.3 ± 2.7 ng/mL. Gal-3 was positively correlated with hs-cTnT (r = 0.384, p < 0.001) and NT-proBNP (r = 0.278, p = 0.006), but not significantly correlated with LVEF or GLS. Gal-3 concentrations did not differ significantly across HFA-ICOS risk categories (p = 0.237). Patients aged ≥65 years had higher Gal-3 concentrations than younger patients (7.1 ± 2.8 vs. 5.7 ± 2.5 ng/mL, p = 0.003). In multivariable median regression, age was the only variable significantly associated with Gal-3 among the covariates included in the model (β = 0.82 ng/mL per 10-year increase, 95% CI 0.21–1.43, p = 0.009). Associations with hs-cTnT and NT-proBNP were no longer statistically significant after adjustment. In patients with breast cancer before anthracycline therapy, baseline Gal-3 concentrations were associated with age after multivariable adjustment, whereas associations with established cardiac biomarkers were attenuated. No significant associations were observed with LVEF or GLS, and Gal-3 concentrations did not differ significantly across HFA-ICOS risk categories in unadjusted analyses.
Related
- Transcriptomic associations and biomarkers in ANCA‑associated Glomerulonephritis and IgG4‑related Disease: A bioinformatics and machine learning study
- Prevalence of amyloidosis among older cardiac patients with left ventricular hypertrophy: a cross-sectional single-centre study in Moscow, Russia.
- Inferring flux-based metabolic fingerprints from gene expression to predict drug response and facilitate patient stratification
- From inherited susceptibility to tumor state: toward a stage-aware architecture for genomic risk stratification in prostate cancer
- Urinary TAGMe methylation enables preoperative risk stratification and reveals enhancer‑mediated regulation in urothelial carcinoma
BibTeX
@article{borowiec2026baseline,
title = {{Baseline Galectin-3 in Patients with Breast Cancer Scheduled for Anthracycline Therapy: Associations with Cardiac Biomarkers, Left Ventricular Function, and HFA-ICOS Risk Stratification}},
author = {Anna Borowiec and Patrycja Ozdowska and Agnieszka Maria Zebrowska and Magdalena Rosinska and Agata Makowka and Beata Puton and Katarzyna Pogoda and Zbigniew Nowecki and Nicola Maurea and Beata Kotowicz},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms272110020},
url = {https://www.mdpi.com/1422-0067/27/21/10020},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Baseline Galectin-3 in Patients with Breast Cancer Scheduled for Anthracycline Therapy: Associations with Cardiac Biomarkers, Left Ventricular Function, and HFA-ICOS Risk Stratification
AU - Anna Borowiec
AU - Patrycja Ozdowska
AU - Agnieszka Maria Zebrowska
AU - Magdalena Rosinska
AU - Agata Makowka
AU - Beata Puton
AU - Katarzyna Pogoda
AU - Zbigniew Nowecki
AU - Nicola Maurea
AU - Beata Kotowicz
PY - 2026
DA - 2026/11/09
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms272110020
UR - https://www.mdpi.com/1422-0067/27/21/10020
AB - The clinical role of galectin-3 (Gal-3) as a biomarker in cardio-oncology remains uncertain. This study evaluated baseline Gal-3 concentrations and their associations with established cardiac biomarkers, left ventricular systolic function, and HFA-ICOS cardiovascular risk categories in patients with breast cancer before anthracycline-based chemotherapy. This cross-sectional baseline analysis included 103 patients enrolled in the EMPACT trial. Gal-3 concentrations were evaluated in relation to high-sensitivity cardiac troponin T (hs-cTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), HFA-ICOS risk categories, and clinical characteristics. Associations were assessed using Pearson correlation analyses and median regression. Mean baseline Gal-3 concentration was 6.3 ± 2.7 ng/mL. Gal-3 was positively correlated with hs-cTnT (r = 0.384, p < 0.001) and NT-proBNP (r = 0.278, p = 0.006), but not significantly correlated with LVEF or GLS. Gal-3 concentrations did not differ significantly across HFA-ICOS risk categories (p = 0.237). Patients aged ≥65 years had higher Gal-3 concentrations than younger patients (7.1 ± 2.8 vs. 5.7 ± 2.5 ng/mL, p = 0.003). In multivariable median regression, age was the only variable significantly associated with Gal-3 among the covariates included in the model (β = 0.82 ng/mL per 10-year increase, 95% CI 0.21–1.43, p = 0.009). Associations with hs-cTnT and NT-proBNP were no longer statistically significant after adjustment. In patients with breast cancer before anthracycline therapy, baseline Gal-3 concentrations were associated with age after multivariable adjustment, whereas associations with established cardiac biomarkers were attenuated. No significant associations were observed with LVEF or GLS, and Gal-3 concentrations did not differ significantly across HFA-ICOS risk categories in unadjusted analyses.
SN - 1422-0067
ER -